Amylin-Based Therapies (CagriSema) Emerge as Well-Tolerated Option with Additive Weight Loss; New Cagrilintide Monotherapy Data
Key Questions
What is CagriSema and how does it work?
CagriSema combines cagrilintide (an amylin analog) with semaglutide, leveraging amylin receptor agonism for additive weight loss. It offers a distinct mechanism from GLP-1 alone.
How does CagriSema compare to GLP-1 therapy alone?
Expert reviews note it delivers greater weight loss with fewer GI side effects than GLP-1 monotherapy. This improved tolerability may support broader use in algorithmic obesity care.
What is the development status of amylin-based therapies?
Novo Nordisk is leading development of CagriSema as a new class entering obesity pharmacotherapy. It is positioned as a well-tolerated option that could enable starting treatment with amylin agonists.
Expert interview at ADA 2026 (Dr. Garvey) highlights CagriSema (cagrilintide + semaglutide) showing additive weight loss with minimal GI side effects compared to GLP-1 alone. Amylin receptor agonism offers a distinct mechanism with good tolerability, potentially enabling algorithmic care starting with amylin. This represents a new class entering the obesity pharmacotherapy landscape, with Novo Nordisk leading development. A commentary on REDEFINE 1 notes lean mass loss (~1/3) warrants attention, especially in older adults. New cagrilintide monotherapy trial data provides direct clinical readout for amylin analog in weight management, adding granularity beyond the CagriSema combo.